Mumbai, Baltimore, February 17, 2022 — Lupin Pharmaceuticals Inc., (Lupin) today announced that the U.S. Food and Drug Administration has approved the company’s supplemental New Drug Application (sNDA) to expand the use of Solosec®…Original Article
Lupin Announces FDA Approval of Supplemental New Drug Application for Solosec (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis
